Moderna to begin clinical trials of COVID booster shots

Doses of a new COVID-19 vaccine which has been designed to provide better protection against a variant of the virus from South Africa has been shipped to the NIH by Moderna. The current two-dose regimen generates a weaker immune response according to Moderna to the strain generated in South Africa. Antibodies still remain above the expected levels to protect against the virus according to Moderna.